1-13
Review
Third-line therapy for metastatic colorectal cancer
M. G. Gundgaard, J. B. Soerensen and E. Ehrnrooth
15-21
Original Article
Modification of multidrug resistance of tumor cells by ionizing radiation
Yuri N. Korystov, Vera V. Shaposhnikova, Antonina F. Korystova, Maksim O. Emel’yanov and Ludmila N. Kublik
23-32
Original Article
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers
Rob J. Jones, Tamsin Boyce, Michael Fennell, Vivien Jacobs and Francesco Pinto, et al.
33-38
Original Article
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy
Li Zhang, Yang Zhang, Pei-Yu Huang, Fei Xu and Pei-Jian Peng, et al.
39-45
Original Article
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin
Alfred F. Furth, Sumithra J. Mandrekar, Angelina D. Tan, Andrea Rau and Sara J. Felten, et al.
47-52
Original Article
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
Jeeyun Lee, Tae-You Kim, Myung Ah Lee, Myung Ju Ahn and Hoon-Kyo Kim, et al.
53-61
Original Article
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer
Yoshihiro Wada, Ken Kikuchi, Wataru Takahashi, Jiro Honda and Juro Nakanishi, et al.
63-73
Original Article
Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate
Lee Jia, Lori C. Coward, Corenna D. Kerstner-Wood, Ronda L. Cork and Gregory S. Gorman, et al.
75-81
Original Article
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
Sang Joon Shin, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho and Hei-Cheul Jeung, et al.
83-88
Original Article
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus
Dae Ho Lee, Heung Tae Kim, Ji-Youn Han, Sung Young Lee and Sung Jin Yoon, et al.
89-96
Original Article
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice
Roni Haklai, Galit Elad-Sfadia, Yaakov Egozi and Yoel Kloog
97-104
Original Article
Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction
Martina Baur, Anne Drescher, Margit Gneist, Christian Dittrich and Ulrich Jaehde
105-111
Original Article
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin
Roberto Petrioli, Alessandra Pascucci, Edoardo Francini, Stefania Marsili and Angela Sciandivasci, et al.
113-123
Original Article
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
G. Vassal, G. Michel, H. Espérou, J. C. Gentet and D. Valteau-Couanet, et al.
125-131
Original Article
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer
T. O’Connor, Y. Rustum, E. Levine and P. Creaven
133-144
Original Article
Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycin
Jaime A. Yáñez, M. Laird Forrest, Yusuke Ohgami, Glen S. Kwon and Neal M. Davies
145-155
Original Article
Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria
N. A. G. Santos, C. S. Catão Bezerra, N. M. Martins, C. Curti and M. L. P. Bianchi, et al.
157-165
Original Article
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Hye Jin Choi and Byoung Chul Cho, et al.
167-175
Clinical Trial Report
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis
Robert L. Fine, David R. Fogelman, Stephen M. Schreibman, Manisha Desai and William Sherman, et al.
177
Erratum
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis
Robert L. Fine, David R. Fogelman, Stephen M. Schreibman, Manisha Desai and William Sherman, et al.